Supplementation With Fish Oil in Pregnancy Reduces Gastroenteritis in Early Childhood

J Infect Dis. 2023 Feb 1;227(3):448-456. doi: 10.1093/infdis/jiab607.

Abstract

Background: We hypothesized that insufficient intake of fish oil-derived omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) during pregnancy is a contributing factor to gastroenteritis in early childhood. We examined the effect of n-3 LCPUFA supplementation on gastroenteritis symptoms in the offspring's first 3 years of life.

Methods: This was a double-blinded, randomized controlled trial whereby 736 mothers were administered n-3 LCPUFA or control from pregnancy week 24 until 1 week after birth. We measured the number of days with gastroenteritis, number of episodes with gastroenteritis, and the risk of having a gastroenteritis episode in the first 3 years of life.

Results: A median reduction of 2.5 days with gastroenteritis (P = .018) was shown, corresponding to a 14% reduction in the n-3 LCPUFA group compared with controls in the first 3 years of life (P = .037). A reduction in the number of gastroenteritis episodes (P = .027) and a reduced risk of having an episode (hazard ratio, 0.80 [95% confidence interval, .66-.97]; P = .023) were also shown.

Conclusions: Fish oil supplementation from the 24th week of pregnancy led to a reduction in the number of days and episodes with gastroenteritis symptoms in the first 3 years of life. The findings suggest n-3 LCPUFA supplementation as a preventive measure against gastrointestinal infections in early childhood.

Clinical trials registration: NCT00798226.

Keywords: fish oil; gastroenteritis; pediatrics; pregnancy supplementation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Dietary Supplements
  • Fatty Acids, Omega-3* / therapeutic use
  • Female
  • Fish Oils / therapeutic use
  • Gastroenteritis* / prevention & control
  • Humans
  • Pregnancy

Substances

  • Fish Oils
  • Fatty Acids, Omega-3

Associated data

  • ClinicalTrials.gov/NCT00798226